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Abstract: The K-ras gene is frequently mutated in colorectal cancer and has been associated with tumor initia-
tion and progression; approximately 90% of the activating mutations are found in codons 12 and 13 of exon 1
and just under 5% in codon 61 located in exon 2. These mutations determine single aminoacidic substitutions in
the GTPase pocket leading to a block of the GTP hydrolytic activity of the K-ras p21 protein, and therefore to its
constitutive activation. Point mutations in sites of the K-ras gene, other than codons 12, 13 and 61, and other
types of genetic alterations, may occur in a minority of cases, such as in the less frequent cases of double muta-
tions in the K-ras gene. However, all mutations in this gene, even those which occur in non-canonical sites or
double mutations, are relevant oncogenic alterations in colorectal cancer and may underlie K-ras pathway hy-
peractivation. In the present study, we report the case of a patient with colorectal cancer presenting a concur-
rent point mutation in exons 1 and 2 of the K-ras gene, a GGT to TGT substitution (Glycine to Cysteine) at
codon 12, and a GAC to AAC substitution (Aspartic Acid to Asparagine) at codon 57. In addition, we found in
the same patient’s sample a silent polymorphism at codon 11 (Ala11Ala) of exon 1. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 4, pp. 729–733)
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Introduction
The human ras gene family is one of the potential
targets for mutational changes that play a role in hu-
man tumorigenesis. Members of the ras family of
genes (K-ras, H-ras and N-ras) encode for a 21 kDa
protein (p21) located on the inner surface of the plas-
ma membrane with a farnesyl molecule attached to
its carboxy-terminus [1]. K-ras is a proto-oncogene
located on chromosome 12p12.1 and is activated by
point mutations that occur at the critical hot-spot
coding sequences [1]. The K-ras gene is frequently
mutated in colorectal cancer and it has been associ-
ated with colorectal cancer initiation and progression.
Once acquired, K-ras mutations are preserved
throughout the natural history of tumor development
and are excellent targets for diagnostic testing. These
mutations determine the constitutive activation of the
K-ras protein mainly thorough abrogation of its GTP-
-hydrolytic function. A permanently activated K-ras
pathway escapes from the control of anti-epidermal
growth factor (EGFR) agents which conversely exert
anticancer effects by inhibiting a non-mutated (wild-
-type) physiologically competent EGFR/K-ras signal
[1]. K-ras mutational status has recently been dem-
onstrated to be highly predictive of the activity of two
monoclonal antibodies linked with EGFR (cetuximab
and panitumumab); therefore the exclusion of such
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drugs in the presence of mutated K-ras is becoming
a standard in clinical practice [1]. Approximately 90%
of the activating mutations leading to a block of the
GTP hydrolytic activity of the K-ras-p21 protein, are
found in codons 12 (GGT) and 13 (GGC) of exon 1
and nearly 5% in codon 61 (CAA) located in exon 2
[2]. The most frequently observed types of mutations
are G > A transitions [3], and G > T transversions
[4]. These alterations have been found associated with
gender and sub-localization of the tumor [5]. Other
authors have reported clinical cases presenting se-
quence variants in other codons, even without muta-
tions in codons 12–13.
All mutations and polymorphisms in coding and
not coding regions of the K-ras gene are available on
the websites: www.sanger.ac.uk/genetics/CGP/cosmic/
and dbSNP: www.ncbi.nlm.nih.gov/SNP/. While mu-
tations in codon 12 are well documented, a few au-
thors have also reported mutations in codons 11 and
57, such as the cases of double mutations in the K-ras
gene.
In the present study, we report for the first time
a colon cancer patient presenting a polymorphism at
codon 11 and point mutations at codons 12 (exon1)
and 57 (exon 2), concurrently.
Material and methods
A colon cancer paraffin-embedded tissue of a 79 year-old
male diagnosed with metastatic colorectal cancer and who
had undergone surgical resection, was referred to our Insti-
tutions following a request from the oncologist. Histologi-
cal diagnosis was a moderately differentiated adenocarci-
noma of the colon-rectum (G2) infiltrating the subserosal
adipose tissue (T3) and showing glandular structures with
atypical epithelium and some mitotic figures.
Molecular analysis of K-ras was carried out from DNA
extracted by the paraffin-embedded tumor sections. Tumor
and tumor-free areas were identified within 15 μm-thick
deparaffinized sections lightly counterstained with hema-
toxylin and microdissected by gentle scraping with sterile
scalpels into 1.5 ml polypropylene vials, using a hematoxy-
lin and eosin-stained step section from the same block. DNA
extraction from the microdissected area was performed as
previously reported [6]. Exons 1 and 2 of K-ras were indi-
vidually amplified using a ‘seminested’ amplification proto-
col [7]. DNA extractions and set-up of PCR reactions were
performed in a different laboratory. Direct sequencing re-
actions were performed using a Big Dye Terminator (Ap-
plied Biosystems, Foster City, CA, USA), and run on an
ABI 3130 Genetic Analyzer (Applied Biosystems). In or-
der to exclude pre-analytical and analytical errors, all se-
quencing analyses were carried out on both strands and were
repeated on PCR products obtained from new nucleic acid
extractions. In order to separate alleles and assess the loca-
tion in cis or trans of the variations on codons 11 and 12, the
amplified product was cloned into Pcr4-TOPO Vector us-
ing TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA)
and the haplotypes of each heterozygote were purified and
sequenced.
All analysis was confirmed in duplicate experiments also
in this case, using independently extracted DNA samples.
A further genetic characterization of other molecular mark-
ers was not feasible due to insufficiency of extracted nucle-
ic acids and the paraffin tissue.
Results and discussion
Direct sequencing of tumor-derived PCR products
identified two heterozygous point mutations on exon
1 which led to a substitution of Cysteine for Glycine
(TGT to GGT) at codon 12 and a silent variant (GCC
to GCT) involving Alanine at codon 11 (Figure 1). In
addition, in exon 2 a sequence variant in codon 57
was identified, determining a substitution of Aspar-
agine for Aspartic Acid (AAC to GAC). The results
of PCR analysis of exon 1 were cloned and the haplo-
types of each heterozygote were sequenced in order
to confirm whether the exon 1 sequence variants oc-
curred in the same or different alleles. By cloning the
PCR products into TOPO TA Cloning Kit, we dem-
onstrated the presence of sequence variants in codons
11 and 12 on the same allele (Figure 1). It was not
possible to extend the analysis to Gly12Ala and
Asp57Asn variants, due to the excessive intronic re-
gion length (17,861 bp Ensamble # ENSE00001428812)
and to the nature of the source paraffin tissue.
Concurrent mutations detected during mutation-
al analysis of K-Ras gene have until now been consid-
ered to be relatively rare. The most widely described
case in literature concerns a patient with colon can-
cer who presented concurrent point mutations of the
K-ras oncogene at codons 12 (Gly12Ser) and 22
(Glu22Arg). This study, published in 2002, focused
attention for the first time on determining the pres-
ence of the double mutation in heterozygosity or on
the same allele [8]. In a recent study performed on 186
adenocarcinomas and 16 adenomas from the EPIC-
Norfolk study, one sample, harboring a double muta-
tion at codons 19 (Leu to Phe) and 20 (Thr to Ala),
showed these two changes based on the same allele [9]
In fact, a few previous studies had exclusively de-
scribed the double mutations at codon 12, consequent-
ly assuming that these concurrent mutations inevita-
bly affected both alleles [10, 11]. Sato et al., using dot
blot hybridization, reported a double codon 12 muta-
tion from wild type GGT (Gly) to GAT (Asp) and
GCT (Ala), observed in a case of human endometri-
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al carcinoma [10]. Using a novel multiplex PCR/li-
gase detection to analyze 144 paraffin-embedded ar-
chival colon carcinomas, Khanna et al. identified
a novel double mutation in codon 12 consisting of
a concomitant presence of Asp and Cys, instead of Gly
[11]. However, the screening methods used in these
two studies, such as dot blot hybridization or multi-
plex PCR/ligase, were not able to proceed with a con-
sequent allelic separation [10, 11]. Most studies in
which double mutations have been identified on dif-
ferent codons have not assessed the allelic distribu-
tion of the K-ras variants.
In a screening of 136 colorectal cancers, Jönsson
et al. identified 53 K-ras mutations, of which two had
double variants in codon 12 and 13 and one had mul-
tiple concurrent variants in codon 12 [12].
In order to investigate the incidence of point mu-
tations at K-ras codons 12, 13 and 61, a study con-
ducted on 101 colorectal tumor specimens from
a Mexican population reported two patients with a dou-
ble mutation of codon 12 and one with a concurrent
point mutation at codon 12 and 13 [3]. Two recent
experimental studies performed on tumors derived
from animal models, despite showing the presence of
double mutations, did not focus on evaluating the al-
lelic distribution of concurrent K-ras mutations
[13, 14]. Moreover, in two mice ethylene oxide in-
duced lung cancers, Hong et al. detected K-ras dou-
ble mutations concurrently in codons 12 and 13, and
12 and 61, respectively [13].
In a recent study conducted in pancreas tumor
biopsies obtained from 222 patients, Guo et al.
identified a new K-ras mutation at codon 76
(Glu76Gly), simultaneously with a codon 12
(Gly12Val) Ras mutation [14]. An accurate analy-
sis of the allelic distribution of multiple K-ras mu-
tations was described in a recent paper performing
an extensive mutational screening on 236 gas-
trointestinal human tumors [15]. In this work,
Kimura et al. reported four colorectal cancer and
one gastric cancer cases with double K-ras codon
12 and 13 mutations. Allelic separation confirmed
the presence of point mutations on different alle-
les, suggesting the simultaneous presence of dif-
ferent cell clones in the same tumor, with only one
mutation per clone [15].
Figure 1. Direct sequencing of the PCR products showing substitutions of GCT (Ala) to GCC (Ala) at codon 11,
GGT (Gly) to TGT (Cys) at codon 12 (A) and GAC (Asp) to AAC (Asn) at codon 57 (B). TOPO TA cloning sequencing
of exon 1of K-ras PCR product showing a normal allele (C) and the concurrent presence of the sequence variants in
codons 11 and 12 on the same allele (D)
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These considerations may be in agreement with
the theory that even a single mutation of K-ras is suf-
ficient to sustain the cancer cell and to explain the
mechanisms of neoplastic progression [15]. Another
paper reports the case of a patient with metachro-
nous double lung cancers, which occurred over a pe-
riod of four years, presenting two different mutations
in codon 12 of K-ras gene. In the first tumor, a vari-
ant Gly12Val was described, while the second episode
of lung cancer presented a Gly12Cys, proving the
metachronous nature of these double cancers [16].
In our study, in addition to the canonical sequence
variant at codon 12 (Gly12Cys), we also detected an
unusual silent polymorphism on codon 11 (Ala11Ala)
and a novel GAC to AAC substitution at codon 57
(Asp57Asn). In a study performed on 161 patients
with various forms of hematologic malignancies, Ahu-
ja et al. reported, in one case, a codon 11 mutation
with a threonine for alanine substitution [17]. Two
novel codon 11 missense mutations (Gly11Pro and
Gly11Val) were described in an Italian study per-
formed on 34 cases of gastric cancer. These authors
suggested that these point mutations in codon 11, not
previously reported, might result in transformation,
since codon 10 of similar gene H-ras has been shown
to be transforming when altered by site-directed mu-
tagenesis [6]. In a study performed on DNA from
peripheral blood of lung cancer patients, Gu et al.
argued that codon 11 CCT (Pro) instead of GCT (Ala)
was a frequent polymorphism in a Chinese popula-
tion [18]. More recently, Zaravinos et al. reported, in
23 cases of human nasal polyps, in addition to classi-
cal mutations at codon 12 of K-ras gene, evidence for
an unusually high frequency of mutations in codon
11, without sequence variants in codon 13. All muta-
tions in codon 11 were homozygous and in six cases
were concurrent with mutations in codon 12 [19].
Unlike the codon 11, to our knowledge, there are no
reports that describe human sequence variants on
codon 57 of K-ras gene. In vitro studies have demon-
strated that the Ras mutant, in which Asp57 is re-
placed with tyrosine (Asp57Tyr), abolished the insu-
lin-induced increase in mitogen-activated protein ki-
nase activity [20], while a previous study showed that
Asp57 in p21ras plays a considerable biological role,
since it is a part of the switch region II of G proteins
[21]. In our findings, it was not identified whether this
Asp57 mutation gives rise to tumorigenesis. The cur-
rently available biotechnologies, applicable to paraf-
fin extracted nucleic acids, in most cases degraded,
have not allowed the allelic separation involving both
exons, so that it is not possible to determine if a dou-
ble mutation is present in one or two distinct cellular
clones. Heterogeneity in the tumor tissue with multi-
ple K-ras gene alterations in the same tumor has been
documented, suggesting that different cellular clones
arising from the same original transformed cell may
harbor different genetic disruptions of the same gene
[8, 15]. Recent evidence suggests the reason for het-
erogeneity of colon cancer, providing a plausible
model to explain the sequence of events and molecu-
lar somatic alterations for the major pathways in-
volved in colorectal cancer progression [22]. How this
mutational ‘clonality’ of K-ras may overall influence
cancer growth is still unknown, even though these
mutations must be late changes in tumor progression.
It is imperative that there should be further studies
to clarify the biological activity of combination in point
mutations at exon 1 and 2.
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